The colorectal cancer market in South & Central America is expected to grow from US$ 681.70 million in 2022 to US$ 814.50 million by 2028; it is estimated to grow at a CAGR of 2.2% from 2022 to 2028.
The market for colorectal cancer in the region is expected to grow owing to rise in the incidences of colorectal cancer and increase in the demand for colonoscopy procedures in Brazil. The market is also attributed to grow in Argentina due to the rising advancement for the technology to prevent incidences of the cancers.
The Rest of South & Central America colorectal cancer market is segmented into Chile, Peru, Ecuador, and other countries. According to GLOBOCAN 2020 data, there were approximately 6,219 new colorectal cancer cases in Chile, representing 11.5% of all new cancer cases in both genders, and ~4,636 new colorectal cancer cases were diagnosed in all ages in Peru.
Moreover, the majority of the countries in Latin America lack adequate systematic screening or prevention programs. The general screening of people aged above 50 years is a cost-effective and efficacious way of reducing colorectal cancer. Several South & Central American countries have developed national guidelines for early detection, management, and follow-up of colorectal cancer. Further, Uruguay has implemented colorectal cancer screening programs, while Chile, Cuba, and Ecuador have initiated pilot studies.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South & Central America colorectal cancer market at a substantial CAGR during the forecast period.
The market for colorectal cancer in the region is expected to grow owing to rise in the incidences of colorectal cancer and increase in the demand for colonoscopy procedures in Brazil. The market is also attributed to grow in Argentina due to the rising advancement for the technology to prevent incidences of the cancers.
The Rest of South & Central America colorectal cancer market is segmented into Chile, Peru, Ecuador, and other countries. According to GLOBOCAN 2020 data, there were approximately 6,219 new colorectal cancer cases in Chile, representing 11.5% of all new cancer cases in both genders, and ~4,636 new colorectal cancer cases were diagnosed in all ages in Peru.
Moreover, the majority of the countries in Latin America lack adequate systematic screening or prevention programs. The general screening of people aged above 50 years is a cost-effective and efficacious way of reducing colorectal cancer. Several South & Central American countries have developed national guidelines for early detection, management, and follow-up of colorectal cancer. Further, Uruguay has implemented colorectal cancer screening programs, while Chile, Cuba, and Ecuador have initiated pilot studies.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South & Central America colorectal cancer market at a substantial CAGR during the forecast period.
South & Central America Colorectal Cancer Market Segmentation
The South & Central America colorectal cancer market is segmented into modality, and end user, and country.- Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment holds the largest market share and is expected to register the highest CAGR during the forecast period.
- Based on end user, the global colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment holds a larger market share.
- Based on country, the South & Central America colorectal cancer market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America held the largest market share in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. SAM Colorectal Cancer- Market Landscape
5. SAM Colorectal Cancer Market - Key Market Dynamics
6. SAM Colorectal Cancer Market- SAM Analysis
7. SAM Colorectal Cancer Market Analysis - By Modality
8. SAM Colorectal Cancer Market Revenue and Forecast To 2028 - By End User
9. SAM Colorectal Cancer Market Revenue and Forecast to 2028 - Country Analysis
10. Colorectal Cancer Market - Industry Landscape
11. Company Profiles
12. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Amgen Inc.
- Bruker Corporation
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Quest Diagnostics
- VolitionRx Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 152 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 681.7 Million |
| Forecasted Market Value ( USD | $ 814.5 Million |
| Compound Annual Growth Rate | 2.2% |
